Inspire Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Inspire Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-79	Closed	–	–	787
2020 Q4	$0	Buy	+79	New	+$333	﹤0.01%	825

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Inspire Advisors's BLCM Position: Q1 2021 in Review

Inspire Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2021, closing a stake of 79 shares.

Inspire Advisors first reported a position in BLCM in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2021.

Inspire Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 79 Bellicum Pharmaceuticals, Inc. shares in Q1 2021.
Inspire Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $0 in Q4 2020.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.